MYNZ Stock Summary and Trading Ideas (Mainz Biomed N.V. - | NASDAQ:MYNZ)

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Mainz Biomed N.V. - trades on the NASDAQ stock market under the symbol MYNZ.

As of December 17, 2025, MYNZ stock price climbed to $1.07 with 256,478 million shares trading.

MYNZ has a beta of 2.04, meaning it tends to be more sensitive to market movements. MYNZ has a correlation of 0.10 to the broad based SPY ETF.

MYNZ has a market cap of $9.18 million. This is considered a Sub-Micro Cap stock.

Last quarter Mainz Biomed N.V. - reported $893,991 in Revenue and -$22.36 earnings per share. This beat revenue expectation by $593,991 and missed earnings estimates by -$19.56.

In the last 3 years, MYNZ traded as high as $328.45 and as low as $.92.

MYNZ has underperformed the market in the last year with a price return of -77.4% while the SPY ETF gained +11.8%. MYNZ has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.0% and -7.8%, respectively, while the SPY returned +2.0% and -1.5%, respectively.

MYNZ support price is $.93 and resistance is $1.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MYNZ shares will trade within this expected range on the day.